Abstract
Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.
Original language | English |
---|---|
Pages (from-to) | 2803-2808 |
Number of pages | 6 |
Journal | Internal Medicine |
Volume | 58 |
Issue number | 19 |
DOIs | |
Publication status | Published - 2019 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Internal Medicine